Key facts

Active Substance
Marizomib
Therapeutic area
Oncology
Decision number
P/0403/2019
PIP number
EMEA-002452-PIP01-18
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of malignant glial tumours
Route(s) of administration
Intravenous use
Contact for public enquiries

Celgene Europe B.V.

Tel. +41 327298500
E-mail: medinfo.emea@celgene.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

P/0403/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for marizomib (EMEA-002452-PIP01-18)

How useful do you find this page?